VXRT Vaxart, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 72444 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.3%
TTM net income YoY157.3%
TTM EPS YoY—
Revenue 3-yr CAGR252.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin16.6%
Net margin16.0%
FCF margin17.6%
EBITDA margin19.3%
Returns
ROE62.4%
ROA16.3%
ROIC (approx.)143.3%
Asset turnover1.02x
Leverage & solvency
Liabilities / assets55.3%
Debt / equity0.00x
Current ratio1.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.13x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $237.26M | $28.70M |
| R&D expense | $201.58M | $74.21M |
| SG&A expense | $17.61M | $20.78M |
| Operating income | $18.07M | -$66.29M |
| Pretax income | $16.80M | -$66.69M |
| Income tax | $476,000 | $260,000 |
| Net income | $16.33M | -$66.95M |
| EBITDA | $26.65M | -$57.44M |
| EPS (basic) | 0.07 | -0.33 |
| EPS (diluted) | 0.07 | -0.33 |
| Weighted avg. shares (diluted) | 230.35M | 202.14M |
| Balance sheet | ||
| Cash & equivalents | $53.81M | $25.23M |
| Short-term investments | $9.99M | $26.49M |
| Receivables | $14.56M | $5.76M |
| Current assets | $136.12M | $68.26M |
| PP&E, net | $5.43M | $8.71M |
| Goodwill | $4.51M | $4.51M |
| Intangibles | $2.83M | $3.56M |
| Total assets | $186.08M | $166.39M |
| Current liabilities | $86.75M | $90.88M |
| Total liabilities | $98.28M | $107.46M |
| Shareholders' equity | $87.80M | $58.92M |
| Shares outstanding | 240.49M | 227.77M |
| Cash flow statement | ||
| Operating cash flow | $7.71M | -$44.76M |
| Capital expenditure | $145,000 | $554,000 |
| Free cash flow | $7.57M | -$45.32M |
| Investing cash flow | $16.63M | -$21.32M |
| Financing cash flow | $4.24M | $56.56M |
| Depreciation & amortization | $8.58M | $8.85M |
| Stock-based compensation | $8.31M | $11.50M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.